Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 7Recruiting 2Withdrawn 1Unknown 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 4CNS 4Thoracic 3Dermatologic 3Breast 3Sarcoma 2Lymphoid 2Genitourinary 2Gastrointestinal 2Gynecologic 1Endocrine 1

Conditions

Neuroendocrine Tumors 46Pituitary Neoplasms 19Neoplasms 14Thyroid Neoplasms 13Pheochromocytoma 13Thyroid Carcinoma, Anaplastic 12Thyroid Cancer, Papillary 12Neoplasm Metastasis 12Adrenocortical Carcinoma 11Paraganglioma 9Insulinoma 9Carcinoid Tumor 9Adrenal Gland Neoplasms 9Somatostatinoma 8Glucagonoma 8Colorectal Neoplasms 8Carcinoma, Renal Cell 8Carcinoma, Islet Cell 8Pancreatic Neoplasms 7Gastrinoma 7Carcinoma, Neuroendocrine 7Breast Neoplasms 7Melanoma 6Head and Neck Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Adenoma, Islet Cell 6Small Cell Lung Carcinoma 5Multiple Endocrine Neoplasia Type 1 5Lung Neoplasms 5Gastro-enteropancreatic neuroendocrine tumor 5

Interventions

pentetreotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Esthesioneuroblastoma, Olfactory × Endocrine × Clear all
NCT00002947 2014-07-02

Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer

Yale University

Phase 1 Terminated
35 enrolled
CNSDermatologicEndocrineGenitourinaryHead & NeckThoracic

Uveal Melanoma, Carcinoma, Renal Cell, Vipoma, Glucagonoma, Head and Neck Neoplasms, Insulinoma, Adenoma, Islet Cell, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Pheochromocytoma, Somatostatinoma, Carcinoma, Merkel Cell, Gastrinoma, Central Nervous System Neoplasms, Carcinoma, Islet Cell, Carcinoma, Medullary, Esthesioneuroblastoma, Olfactory, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡